The entire bull-bear debate collapses to one auditor's signature, due in 28 days.

• 30 May 2026. The FY26 audited annual report is due under SEBI LODR Reg 33 — the new auditor's first opinion on this company. Until that disclosure lands, every other data point on the page supports both readings.
• Bull's path to ₹35. A clean opinion plus inventory days under 300 plus CFO/NI above 0.7 re-rates the equity to roughly 1.5× book — Insecticides India's peer multiple, with the forensic discount lifted.
• Bear's path to ₹10. Any qualification, key-audit-matter on inventory or related parties, or going-concern note opens the path to a ~₹400 cr write-down — book collapses from ₹22.8 to ~₹10 a share, the level the March-2026 ₹12.33 low briefly pretended to.

Inventory was 67 days in FY22. It is 864 days in FY25. Pick a story.

Four years of reported earnings (₹440 cr) generated negative cash (−₹191 cr) — no peer in listed Indian agrochem has a comparable disconnect; even UPL converts at roughly 1×. The build was financed by stretching suppliers from 72 to 521 days. The bull reads the H1 FY26 ₹160 cr borrowings drawdown — at a 32% gross margin held in the trough quarter — as proof the inventory is real and converting. The bear reads it as saleable stock liquidating first while ~₹400 cr of impaired residue still carries at cost. The audited FY26 inventory-days line decides which.

Patented sales fell 5%; generics fell 48%. The market is pricing both at zero.

• The split is in the disclosure. 9M FY26: patented portfolio (Ronfen, Tricolor, Defender, Orisulam — ₹357 cr in FY25) declined 5% YoY; the rest of the book fell 48%. Q3 FY26 gross margin held at 32% on revenue down 31% — pull-driven economics, not push-driven distress.
• The patented share went from zero to 30%. Eight launches in three years on the back of CIB&RC 9(3)/9(4) registrations and in-house Diafenthiuron synthesis — the only category management has reliably hit while missing every revenue and margin guide.
• The arithmetic is uncomfortable. Apply Dhanuka's 4× sales to the ₹357 cr patented book alone and you get ₹1,400 cr — more than the entire ₹637 cr equity market cap. The bulk business is being valued at less than zero.

Two directors, the statutory auditor, and the company secretary all walked between July and October 2025.

• Cluster of exits. 2 Jul 2025: two directors resigned the same day with no public reason — one an executive WTD on ₹1.95 cr, the other the chair of the Stakeholder Relationship Committee. 14 Aug 2025: Walker Chandiok resigned as statutory auditor. October 2025: the Company Secretary followed.
• Foreign money agreed. FII ownership halved from 10.84% (Q2 FY24) to 5.63% (FY26) over the same drawdown. Only one mutual fund (Quant Small Cap, 0.04% AUM) sits on the register. Retail base doubled into the fall — the wrong direction for institutional discovery.
• The founder is the offsetting fact. He owns 47.95% personally, 50.44% with the group, zero pledge, zero selling — and personally subscribed ₹37 cr of warrants at ₹640 (effective ₹42 post split-and-bonus) when the spot was already ₹18. Walker Chandiok signed FY25 unqualified before resigning; auditors who object to client accounting almost always resign before signing, not three months after.